Article Text

PDF
Agomelatine improves symptoms of generalised anxiety disorder

Statistics from Altmetric.com

QUESTION

Question:

Is agomelatine effective for people with generalised anxiety disorder?

Patients:

121 people, aged 18–65 years, with DSM-IV generalised anxiety disorder (69% female, mean age 42 years) (see online notes for exclusion criteria).

Setting:

Five centres in Finland and six centres in South Africa; time period not stated.

Intervention:

Agomelatine (n = 63; 25–50 mg/day) or placebo (n = 58) for 12 weeks. Agomelatine dose was increased from 25 to 50 mg/day if there was an insufficient response after 2 weeks. This was done in a blinded fashion, using a dose adjustment algorithm.

Outcomes:

Primary outcome: overall anxiety (HAM-A). Secondary outcomes: response (⩾50% reduction in HAM-A score); somatic anxiety, psychic anxiety, severity of illness, sleep and disability symptoms (HAM-A subscales, Clinical Global Impressions Scale, Leeds Sleep Evaluation Questionnaire and Sheehan Disability Scale); discontinuation effects in the week after discontinuation (Discontinuation Emergent Signs and Symptoms scale (DESS)). Last observation …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.